Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05512754 · ClinicalTrials.gov registry record · Phase 4
Impact of Anti-inflammatory Medications in Patients With Elevated Serum Prostate-specific Antigen
A Phase 4 study of Elevated Serum PSA, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 3
- Study locations
NCT05512754: Recruiting Phase 4 study of Elevated Serum PSA, sponsored by University of Chicago.
NCT05512754 is a Phase 4 study of Elevated Serum PSA that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 200 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (61% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05512754, a Phase 4 study of Elevated Serum PSA, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to assess the impact of ibuprofen in men with elevated serum PSA.
Primary Outcome
serum prostatic specific antigen
Conditions Studied
Interventions
- DRUG Ibuprofen 400 mg
Study Locations (3)
Illinois
- University of Chicago - Chicago
New York
- Albany Medical College - Albany
Pennsylvania
- The Pennsylvania State University at The Milton S. Hershey Medical Center - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-08-01 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 4 |
What NCT05512754 shows while recruiting
NCT05512754 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Elevated Serum PSA appearing as the primary indexed condition, and to 1 intervention - of which Ibuprofen 400 mg is the first listed.
NCT05512754 reports a single indexed study location in Illinois, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05512754 about?
NCT05512754 is a clinical study titled "Impact of Anti-inflammatory Medications in Patients With Elevated Serum Prostate-specific Antigen". The purpose of this study is to assess the impact of ibuprofen in men with elevated serum PSA.
What is the current status of trial NCT05512754?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2022-08-01. Estimated completion is 2027-12-31.
What conditions does trial NCT05512754 study?
This clinical trial studies the following conditions: Elevated Serum PSA.
What interventions are being tested in trial NCT05512754?
The interventions under investigation include: Ibuprofen 400 mg (DRUG).
Who is sponsoring clinical trial NCT05512754?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05512754 being conducted?
This trial has 3 study locations across Illinois, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05512754's enrollment target sits among peer trials
200 407th of 2000 higher than 1,557 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI